IVEVF (Inventiva) Tax Provision: $-0.04 Mil (TTM As of Dec. 2025)


IVEVF Inventiva SA IVEVF
40 GF Score
Price $3.59
GF Value $0.27
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Inventiva Tax Provision?

Inventiva IVEVF 40 Tax Provision is $-0.04 Mil as of Dec. 2025. GuruFocus rates IVEVF with a GF Score™ of 40/100 and a GF Value™ of $0.27 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Inventiva's tax provision for the six months ended in Dec. 2025 was $-0.62 Mil. Its tax provision for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.04 Mil.

Inventiva Tax Provision Historical Data

* Premium members only.

The historical data trend for Inventiva's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inventiva Tax Provision Chart

Inventiva Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Tax Provision
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.41 0.02 -0.66 -0.33 -0.03

Inventiva Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Tax Provision Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.67 -0.13 -0.20 0.58 -0.62
IVEVF
40GF Score
Inventiva SA IVEVF
Tax Provision is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Inventiva Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.04 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Provision →
What does a Tax Provision of $-0.04 Mil mean?
Inventiva (IVEVF) has a Tax Provision of $-0.04 Mil as of Dec. 2025. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Inventiva and its competitors.
Is Inventiva's Tax Provision too high?
Inventiva's current Tax Provision is $-0.04 Mil. Overall, Inventiva has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Inventiva's Tax Provision compare to VRTX and REGN?
Inventiva's Tax Provision of $-0.04 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Provision for a Biotechnology company?
A good Tax Provision depends on the Biotechnology industry context. However, Tax Provision should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Provision mean?
A high Tax Provision can signal that a stock is expensive relative to its fundamentals. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Inventiva and its competitors. Inventiva's current Tax Provision is $-0.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inventiva stock overvalued right now?
Based on GuruFocus' analysis, Inventiva (IVEVF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.27, compared to a current price of $3.59 — trading 1229.6% above its estimated fair value. The current Tax Provision is $-0.04 Mil. Inventiva's overall GF Score™ is 40/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Provision calculated?
Tax Provision is calculated from a company's financial statements. For Inventiva (IVEVF), the current Tax Provision is $-0.04 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Inventiva (IVEVF) Overvalued in 2026?

Based on GuruFocus' analysis, Inventiva stock appears to be overvalued. The current stock price of $3.59 is trading 1229.6% above its estimated GF Value™ of $0.27. GuruFocus considers Inventiva to be Significantly Overvalued.

Key valuation signals for IVEVF:

  • Tax Provision: $-0.04 Mil
  • GF Value™: $0.27 vs. price of $3.59 (1229.6% above fair value)
  • GF Score™: 40/100 with 7 warning signs

No single metric tells the full story. See the IVEVF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Inventiva Business Description

Address 50 rue de Dijon, Daix, FRA, 21121
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.
40GF Score

Get the complete analysis for IVEVF

Tax Provision is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.59
Price
$0.27
GF Value